TPCW
NBIX icon

TD Private Client Wealth’s Neurocrine Biosciences NBIX Stock Holding History

TD Private Client Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33K Buy
196
+43
+28% +$6.38K ﹤0.01% 966
2026
Q1 		$20.2K Buy
153
+10
+7% +$1.33K ﹤0.01% 1005
2025
Q4 		$20.3K Buy
143
+6
+4% +$869 ﹤0.01% 1008
2025
Q3 		$19.2K Sell
137
-45
-25% -$6.1K ﹤0.01% 986
2025
Q2 		$22.9K Buy
182
+38
+26% +$4.36K ﹤0.01% 966
2025
Q1 		$15.9K Buy
144
+65
+82% +$8.23K ﹤0.01% 965
2024
Q4 		$10.8K Hold
79
– – ﹤0.01% 1044
2024
Q3 		$9.1K Hold
79
– – ﹤0.01% 1066
2024
Q2 		$10.9K Hold
79
– – ﹤0.01% 1028
2024
Q1 		$10.9K Buy
79
+18
+30% +$2.46K ﹤0.01% 1029
2023
Q4 		$8.04K Hold
61
– – ﹤0.01% 1073
2023
Q3 		$6.86K Sell
61
-2
-3% -$211 ﹤0.01% 1077
2023
Q2 		$5.94K Hold
63
– – ﹤0.01% 1112
2023
Q1 		$6.38K Hold
63
– – ﹤0.01% 1086
2022
Q4 		$7.53K Hold
63
– – ﹤0.01% 1043
2022
Q3 		$6.69K Buy
63
+2
+3% +$203 ﹤0.01% 1040
2022
Q2 		$5.95K Sell
61
-27
-31% -$2.49K ﹤0.01% 1044
2022
Q1 		$8.25K Buy
+88
New +$7.46K ﹤0.01% 1059
2021
Q4 		– Sell
-15
Closed -$1.44K – 1232
2021
Q3 		$1.44K Hold
15
– – ﹤0.01% 1059
2021
Q2 		$1.46K Hold
15
– – ﹤0.01% 1064
2021
Q1 		$1.46K Sell
15
-38
-72% -$3.98K ﹤0.01% 1025
2020
Q4 		$5.08K Hold
53
– – ﹤0.01% 890
2020
Q3 		$5.1K Hold
53
– – ﹤0.01% 842
2020
Q2 		$6.47K Sell
53
-37
-41% -$4.09K ﹤0.01% 822
2020
Q1 		$7.79K Buy
90
+34
+61% +$3.33K ﹤0.01% 778
2019
Q4 		$6.02K Buy
+56
New +$5.86K ﹤0.01% 802

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TD Private Client Wealth's NBIX Position: Q2 2026 in Review

TD Private Client Wealth increased its Neurocrine Biosciences (NBIX) stake by 28% in Q2 2026, buying an estimated $6.38K and bringing the position to 196 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #966.

TD Private Client Wealth first reported a position in NBIX in Q4 2019 and has held it in 26 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • TD Private Client Wealth held 196 shares of Neurocrine Biosciences worth $33K as of Q2 2026.
  • TD Private Client Wealth bought 43 Neurocrine Biosciences shares in Q2 2026, an estimated $6.38K.
  • Neurocrine Biosciences made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #966 holding.
  • TD Private Client Wealth first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 26 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.